These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35716222)

  • 21. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
    Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
    Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
    Bellodi C; Lidonnici MR; Hamilton A; Helgason GV; Soliera AR; Ronchetti M; Galavotti S; Young KW; Selmi T; Yacobi R; Van Etten RA; Donato N; Hunter A; Dinsdale D; Tirrò E; Vigneri P; Nicotera P; Dyer MJ; Holyoake T; Salomoni P; Calabretta B
    J Clin Invest; 2009 May; 119(5):1109-23. PubMed ID: 19363292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
    Kujawski L; Talpaz M
    Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
    Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
    Häselbarth L; Karow A; Mentz K; Böttcher M; Roche-Lancaster O; Krumbholz M; Jitschin R; Mougiakakos D; Metzler M
    Cancer Immunol Immunother; 2023 Jun; 72(6):1661-1672. PubMed ID: 36602564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
    Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
    Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies in controlling drug resistance in chronic myeloid leukemia.
    Frame D
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.